Indivior PLC Added to S&P SmallCap 600 Index, Enhancing Market Presence
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: PRnewswire
- Market Recognition: Indivior PLC's addition to the S&P SmallCap 600 Index today signifies a substantial enhancement in the company's recognition within capital markets, aligning its presence with its refined U.S. business profile.
- Commitment to Growth: CEO Joe Ciaffoni emphasized the company's dedication to expanding the market share of SUBLOCADE®, its leading first-in-class long-acting injectable treatment for moderate to severe opioid use disorder, which is expected to drive future revenue growth.
- Index Background: The S&P SmallCap 600 Index comprises 600 companies with market capitalizations between $1.2 billion and $8.0 billion, designed to track liquid and financially viable small-cap firms, and Indivior's inclusion is likely to bolster investor confidence.
- Strategic Transformation: By leveraging a simplified operating model, Indivior aims to capitalize on its newly acquired market position to further innovate and develop in the opioid use disorder treatment sector.
INDV
$35.21+Infinity%1D
Analyst Views on INDV
Wall Street analysts forecast INDV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INDV is 38.67 USD with a low forecast of 35.00 USD and a high forecast of 41.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 35.540
Low
35.00
Averages
38.67
High
41.00
Current: 35.540
Low
35.00
Averages
38.67
High
41.00
About INDV
Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.





